speakers

INTERNATIONAL speakers (IN ORDER OF APPEARANCE)

 

DR. MARC BRISSON is an associate professor at Laval University where he holds a Canada Research Chair in Mathematical Modeling and Health Economics of Infectious Diseases. His research aims at developing mathematical models that predict the effectiveness and cost-effectiveness of interventions against infectious diseases to help policy decision-making. His current research mainly focuses on human papillomavirus and varicella-zoster-virus vaccines. Dr. Brisson has produced over 70 peer reviewed journal articles, and made over 100 presentations at conferences, external seminars and workshops (over 35 as invited speaker). He has consulted for the World Health Organization (WHO), the Centers for Disease Control Prevention (CDC), the Canadian Partnership Against Cancer (CPAC), the Public Health Agency of Canada (PHAC) and the Canadian Immunization Committee (CIC). He has a BSc in Actuarial Science (1992-1996), a certificate in Statistics (1996) and an MSc in Epidemiology (1996-2001) from Laval University in Quebec City, and a PhD in Health Economics (1999-2004) from City University in London, England.

PROFESSOR CHRIS MEIJER studied medicine at the Leiden University Medical Center (LUMC) in Leiden,The Netherlands and was graduated as medical doctor in 1972. During this period he also received his PhD. at the Vrije Universiteit Medical Center, (VUMC) Amsterdam in 1971. From 1973 he received his training as surgical pathologist at the LUMC and is board certified as surgical pathologist since 1977 and additionally as medical immunologist in 1981. He worked as a staff pathologist at the dept of Pathology of LUMC till 1980. Then he was appointed as staff member and head of the Department of Immunopathology at the SSDZ, Delft, from 1980-1982. In 1983 he was appointed as prof. in Pathology and from 1983-2009 he was chairman and director of the Dept of pathology of the VUMC, Amsterdam.

He received several awards for his scientific work including the Marie Parijs award (1982), van Vlissingen prize (1999), special awards for excellent contribution to Pathology from the Pathological Society of Great Britain and Ireland (2011) and British Division of the International Academy of Pathology (2011) and was appointed by the queen to “Knight in the order of the Dutch Lion (2010)

He is and has been chairman or member of numerous national and international scientific and strategy committees advising in the field of oncology and pathology.

He leads a large research group aiming to translate basic molecular aspects of HPV infections into cervical cancer
screening practice and into the management of cervical cancer precursor lesions. As such he is also conducting several large clinical trials evaluating the role of self sampling and HPV testing as primary screening tool in optimising cervical cancer screening process.

DR. PHILIP CASTLE is a Research Professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine, Bronx, N.Y., USA, the Executive Director and Co-Founder of Global Cancer Initiative (Chestertown, MD, USA), and the CEO and Co-Founder of the Global Coalition Against Cervical Cancer (Arlington, VA, USA). He is also a Visiting Professor at the Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, P.R. China and Honorary Professor at the University of New South Wales, Sydney, Australia. Previously, Dr. Castle was the Chief Scientific Officer of the American Society for Clinical Pathology (ASCP) (2011-2). He was a Senior, Tenured Investigator (2010-11) and Tenure-Track Investigator (2003-10) in the Division of Cancer Epidemiology and Genetics (DCEG) at the U.S. National Cancer Institute (NCI). He received his Ph.D. in Biophysics in 1995 and M.P.H. in Epidemiology in 2000 from the Johns Hopkins University.

Dr. Castle’s professional interests are (1) epidemiology of human papillomaviruses (HPV) and cervical/anogenital cancer; (2) science and translation of cancer prevention strategies; (3) evidence-based medicine; and (4) international health. While at the NCI, he was the lead investigator on several epidemiologic studies, including the Mississippi Delta Project, The HPV Persistence and Progression Cohort and The Guidelines Cohort at Kaiser Permanente Northern California (KPNC), the Anal Cancer Screening Study. He remains co-PI of The Guidelines Cohort at KPNC and of the Low-Cost Molecular Cervical Cancer Screening Study in China. Dr. Castle is currently conducting research in Australia, Norway, El Salvador, Brazil, Peru, Colombia, Mexico, and Rwanda.

Dr. Castle has published over 250 papers on HPV and cervical cancer and has contributed articles to such prestigious journals as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of the National Cancer Institute, British Medical Journal, JAMA, Archives for Internal Medicine, and Cancer Research. He currently serves on the editorial boards of the Journal of Infectious Diseases and Journal of Lower Genital Tract Disease. Dr. Castle has served as an invited speaker or session chair in many forums, including for the American Association for Cancer Research, International Papillomavirus Society, and the European Union on Genital Infection and Neoplasia (EUROGIN).

Dr. Castle regularly participates in the development of national and international guidelines for cervical cancer prevention. Dr. Castle serves as a consultant for several countries on the development of national cervical cancer prevention programs and is participating in pilot/demonstration projects in El Salvador, Bolivia, and Vietnam. He is currently a member of the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection and Prevention (NBCCEDP) Advisory Committee and member of the Board of Directors of the American Society for Colposcopy and Cervical Pathology (ASCCP).

For his work in cervical cancer prevention, Dr. Castle has received (1) An EUROGIN Distinguished Service Award (2006); (2) a NIH Merit Award for introduction of HPV testing into low-resource settings in the U.S. (2007); (3) a Distinguished Scientific Achievement Award by ASCCP (2010), its highest honor; and (4) The Arthur S. Flemming Award for Exceptional Achievement in Federal Government Service for Applied Science, Engineering and Mathematics (2010).

ASSOCIATE PROFESSOR SHARON HANLEY is a cancer epidemiologist and Assistant Professor in the Department of Women’s Health Medicine at Hokkaido University, Japan. She obtained her PhD. from the Departments of Public Health and Reproductive Endocrinology and Oncology at the same university. She also holds an adjunct position in Hokkaido University Center for Environmental and Health Sciences. Sharon’s research interests include correlates of HPV vaccine acceptance in parents of Japanese girls, attitudes to HPV self-sampling in cervical cancer screening non-attenders and comparative research on cervical cancer screening and HPV vaccination programmes in the UK, Japan and Australia. She is the principal researcher of two grants from the Japanese Society for the Promotion of Science (JSPS); one focusing on cancer education for primary and middle school children and the other looking at using HPV self-sampling to both increase cervical cancer screening uptake in young Japanese woman and evaluate the efficacy of the national Japanese HPV vaccination programme. As well as having an MA (Hons) in Modern Languages from the University of St Andrews, Scotland, she is also undertaking an MPH at London School of Hygiene and Tropical Medicine, focusing her research on health promotion and vaccine confidence.

NATIONAL speakers (IN ORDER OF APPEARANCE)

 

DR JULIA BROTHERTON is a public health physician and Medical Director of Australia’s National HPV Vaccination Program Register. She is a medical graduate from the University of Newcastle, NSW, has a Masters degree in Public Health from the University of Sydney and holds a Fellowship in Public Health Medicine. For the past nine years Julia has been involved in research and policy development informing the implementation and evaluation of HPV vaccination programs in Australia. She has been a lead investigator in Australian research which has demonstrated the world’s first evidence of dramatic declines in both HPV infections and pre-cancerous cervical lesions in young women post- vaccination. She has over 80 publications to date.

MS DINA SAULO is a research officer at the Kirby Institute for infection and immunity in society. She completed a Bachelor of Nursing in 2009 and is currently undertaking a Master of Applied Epidemiology at the Australian National University. Dina has worked for the past 7 years in a public health capacity with a focus largely on sexual reproductive health, sexually transmissible infections and blood borne viruses in a Aboriginal and Torres Strait Islander health and community context.

ASSOCIATE PROFESSOR SEPEHR TABRIZI received his PhD from University of Melbourne in 1990 and has worked in the field of human papillomavirus (HPV) and sexually transmitted infection research since. He currently is the senior scientist in the Molecular Microbiology Laboratory of the Royal Women’s Hospital and Associate Professor at Department of Obstetrics and Gynaecology, University of Melbourne. Currently he is working on the impact of the Australian government cervical vaccine program on circulating HPV genotypes.

PROFESSOR PETER MCINTYRE is the Director of National Centre of Immunisation Research and Surveillance. He trained as a paediatrician and infectious disease physician, completing the FRACP in 1986, and became a Fellow of the Faculty of Public Health Medicine in 1992. His PhD in the epidemiology of invasive Haemophilus influenzae type b (Hib) disease with the School of Public Health, University of Sydney, was completed in 1995.

His current research interests include surveillance and prevention by vaccination of invasive Hib and pneumococcal disease and pertussis, and the use of routinely collected data relevant to Vaccine-Preventable Diseases (VPDs) including the Australian Childhood Immunisation Register (ACIR). He spearheaded the development of hospital-based surveillance for severe VPDs and adverse events following immunisation in Australia – the PAEDS network. He has extensive experience in vaccine trials and is the lead investigator on a NHMRC funded trial of giving acellular pertussis vaccine from birth which has now recruited over 400 babies nationally and a chief investigator on an NHMRC Centres of Research Excellence (CRE) Grant – ‘Immunisation in under studied and special risk populations: closing the gap in knowledge through a multidisciplinary approach’.

In Australia, he is a member of the Australian Technical Advisory Group on Immunisation (ATAGI), the Communicable Diseases Network of Australia (CDNA), and the National Immunisation Committee (NIC). Internationally, he is a member of Working Groups for the WHO Strategic Advisory Group of Experts on Pertussis and Pneumococcal vaccines and was appointed in 2012 to the newly established Immunisation Research Advisory Committee of WHO. He is an invited speaker at international meetings on pertussis and neonatal immunisation. Peter McIntyre is a reviewer for over 10 National and International Journals and an author of over 200 papers and book chapters.

Professor McIntyre has a clinical appointment at The Children’s Hospital at Westmead as a Senior Staff Specialist in Infectious Diseases and a conjoint academic appointment as Professor in the Discipline of Paediatrics and Child Health and in the School of Public Health of the University of Sydney.

PROFESSOR IAN HAMMOND retired in January 2012 after 30 years in clinical practice as a gynaecological oncologist in Perth, Western Australia and Clinical Professor in the School of Women’s and Infants’ Health at the University of Western Australia.

He chaired the group responsible for the development of the 2005 NHMRC endorsed “Screening to Prevent Cervical Cancer: Guidelines to the Management of Asymptomatic Women with Screen Detected Abnormalities”.
Between November 2011 and June 2014 he chaired the Renewal Steering Committee responsible for guiding the ‘renewal process, that led to the 2014 MSAC recommendations underpinning the Renewal.

He is the Chair of the Steering Committee for the Renewal Implementation Project that is guiding the multifaceted and complex process of implementing the new and renewed National Cervical Screening Program.

In 2011, he was awarded the President’s Medal of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists for services to Women’s Health.

He is enjoying an active retirement including photography, reading, travelling and cooking for his wife Frances.

ASSOCIATE PROFESSOR KAREN CANFELL leads the Cancer Screening Group at the Lowy Cancer Research Centre, UNSW Australia. A focus of Karen's research concerns the interplay between HPV vaccination and cervical screening. Her group regularly perform evaluations of new cervical screening and diagnostic technologies and pathways for government agencies in Australia, New Zealand and England. Karen recently led the effectiveness modelling and economic evaluation of a number of potential new pathways and technologies for cervical screening as part of the current Renewal of the National Cervical Screening Program in Australia. She is also co-PI of Compass, a major new trial of cervical screening in the vaccinated population in Australia.

ASSOCIATE PROFESSOR DOROTA GERTIG is a public health physician and has been the Medical Director of the Victorian Cervical Cytology Registry since 2006. She received her medical training at Monash University and a Doctorate in Epidemiology at the Harvard School of Public Health. Assoc Professor Gertig has extensive experience in large epidemiological studies having worked on the Harvard Nurses’ Health Study for over five years and has been chief investigator on several studies including a trial of HPV self-sampling in Victoria. The primary focus of her current work is the on policy relevant research on cervical cancer control and HPV vaccine impact as well as improving participation in cancer screening. She is a member of several Australian and state committees relating to cervical screening and has participated in WHO workshops on comprehensive cervical cancer control in the WPRO region.

ASSOCIATE PROFESSOR JOHN CONDON is a cancer epidemiologist at the Menzies School of Health Research and the Northern Territory Department of Health. He has extensive experience in primary health care service delivery and management in remote Aboriginal communities, and in development of population health monitoring systems at the territory and national levels, particularly relating to Aboriginal health. He was Director of the Northern Territory Cancer Registry for 15 years and continues to work with the Registry. His current research includes investigating cancer incidence and survival, and cervical screening participation and outcomes, for Indigenous Australians nationally, and investigating a cluster of cancer of the vulva in young Aboriginal women in Arnhem Land.


MS LISA WHOP has focused her research to date on improving outcomes for Aboriginal and Torres Strait Islander people with cancer. Her PhD project is focused on the Queensland part of the National Indigenous Cervical Screening Project – the first population-based study in Australia to investigate Indigenous women’s participation in cervical screening and it’s given consequences. She is supported by a Sidney Myer Health Scholarship and a top up from a Menzies Enhanced Living Scholarship funded by the Lowitja Institute.

LOUISE GALLOWAY is Senior Advisor for the Prevention and Population Health (PPH) branch in the Victorian Department of Health. PPH’s work focuses on the development and implementation of primary and secondary prevention policy and program initiatives for Victoria undertaken in conjunction with partner agencies including: government, funded agencies, primary health, other organisations and the community.

Louise’s areas of responsibility include tobacco control, sexual health and viral hepatitis, cancer prevention and population screening, oral health promotion and women’s health. A particular focus of work is to reduce inequality including improving participation in screening programs, with a focus on underscreened communities.

Louise has over ten years’ experience in population screening including overseeing new technology initiatives in cancer screening and prevention. Louise is the Victorian representative on a number of state and national committees, including the Standing Committee on Screening. Louise is also a member of the steering committee overseeing the renewal of the cervical screening program.

Louise has a long history in the health system having first practiced as a radiographer, then undertaking policy roles in both the non-government and government sectors.

Louise has a Master of Business Administration from The University of Melbourne.

PROFESSOR PAUL EFFLER received a Doctorate in Medicine from the University of California and a Master of Public Health from the University of Hawaii.  Upon completing a residency in Public Health Medicine, Dr. Effler served as an Officer in the Epidemic Intelligence Service at the U.S. Centers for Disease Control; he subsequently worked as a consultant to the United Nations High Commissioner for Refugees in Africa and the World Health Organization.  In 1994 he became the State Epidemiologist for Hawaii, where he directed the public health response to SARS, dengue fever, measles, and influenza and oversaw Hawaii’s immunisation program.  In 2008 Dr. Effler moved to Perth where he works in immunisations and communicable disease control. He is an adjunct Professor at UWA and an Associate Editor for Emerging Infectious Diseases at the CDC.    

ASSOCIATE PROFESSOR S. RACHEL SKINNER is a clinical academic and in the Discipline of Paediatrics and Child Health (DPCH), Sydney University at the Children’s Hospital Westmead. She is an adolescent physician and consults in adolescent sexual and reproductive health at the Children’s Hospital Westmead, Sydney.

A/Prof Skinner’s research program and publications broadly address the public health concerns relating to adolescent and young people’s sexual and reproductive health. Specifically, she has published widely on effective school based vaccination programs for adolescents against sexually transmissible diseases, including hepatitis B and most recently against the human papillomavirus (HPV). This has involved research evaluations of the Australian national HPV vaccination program, for adolescents and young adult women. She has also developed and evaluated educational resources for parents, teachers and adolescents on HPV vaccination. She has been/ is a principal investigator on several international HPV clinical trials in adolescents, young and older adult women. She is a recognised opinion leader on the HPV vaccine in Australia for adolescents, young and older women. She has also researched and published widely on factors associated with teenage pregnancy in Australia, teenage sexual behaviour and risk taking and interventions to promote adolescent sexual and reproductive health. She has published over 60 peer reviewed journal articles, many in top tier health journals such as the Lancet. She has edited a textbook on Adolescent and Youth Health, and has written many chapters on adolescent pregnancy and sexual health.

ASSOCIATE PROFESSOR JULIE LEASK is a social scientist specialising in immunisation and NHMRC Career Development Fellow. She is Associate Professor and Sub-Dean (Early Career Researchers) in the School of Public Health, University of Sydney and has an appointment with the Centre for Values, Ethics and the Law in Medicine and the Marie Bashir Institute for Infectious Diseases and Biosecurity. Julie has a background in nursing and midwifery with a Master of Public Health (1998) and PhD (2002) from USYD. She established the Social Science Unit at the Australian National Centre for Immunisation Research and Surveillance between 2002 and 2014 and continues her affiliation there as a visiting fellow. Julie has advised governments in Australia, the US and New Zealand, the Global Vaccine Action Plan, the WHO Europe Regional Office, the US President’s Cancer Panel, US Institute of Medicine, the Australian Academy of Science and the NHMRC on matters related to public acceptance of immunisation.

BIANCA BARBARO is a Research Fellow at the University of Adelaide with a Graduate Diploma in Spatial Information Science. She has expertise in spatial analysis, research, evaluation and project management, with over 14 years in the field of population health research, working for a variety of organisations across government, non-profit agencies and the university sector within Australia and overseas.

Her interests include the analysis of data relating to cancer prevention, including screening, associated risk factors and mortality, geographical analyses at the local area level as well as the utilisation of data for population health research where she has contributed to atlases and reports on health and wellbeing highlighting socioeconomic inequalities in health and in their determinants.

She has worked for the NHS National Services Scotland in the Cancer Surveillance Team where she coordinated the statistical and spatial analysis of the breast, cervical and bowel cancer screening programs, and has worked for the Australian National HPV Vaccination Register (NHVPR) and the Victorian Cervical Cytology Registry (VCCR) with a research focus on under-screened groups, the spatial analysis of cancer screening data and investigating geographic and socioeconomic disparity using registry data.

In addition Bianca is involved in the use of spatial and web technology to access and visualise data online through projects funded under the Commonwealth Government’s AURIN eResearch Infrastructure Network.